Local Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety (incidence of adverse events)
24 weeks
No
Clinical Trials
Study Director
Hoffmann-La Roche
Turkey: Ministry of Health
ML25095
NCT01245439
September 2011
July 2014
Name | Location |
---|